These results suggest that the cell signaling mechanisms controlling PNPLA3 gene expression are similarly affected by momelotinib in hepatocytes and stellate cells, and potentially represent an added therapeutic advantage to using momelotinib to treat NASH. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.